Clinical data | |
---|---|
Trade names | Norvedan |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.038.129 |
Chemical and physical data | |
Formula | C17H12ClNO2S |
Molar mass | 329.80 g·mol−1 |
3D model (JSmol) | |
Melting point | 162–163 °C (324–325 °F) |
| |
| |
NY (what is this?) (verify) |
Fentiazac is a thiazole-based nonsteroidal anti-inflammatory drug (NSAID) developed for use in joint and muscular pain.[1] Like most other NSAIDs, it acts through inhibition of prostaglandin synthesis, via non-selective inhibition of both COX-1 and COX-2. First described in 1974, it was synthesized using the Hantzsch thiazole synthesis.[2]
Fentiazac was marketed under the trade-name Norvedan (among others), but its market status is currently unknown and assumed to be discontinued.[3]
pyrazolones / pyrazolidines | |
---|---|
salicylates | |
acetic acid derivatives and related substances | |
oxicams |
|
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
Anti-inflammatory preparations, non-steroids |
| ||||||
---|---|---|---|---|---|---|---|
Capsaicin derivatives | |||||||
Other |
Receptor (ligands) |
| ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Enzyme (inhibitors) | |||||||||||||||||
Others | |||||||||||||||||